By Catholic Review Staff
The bridge board for the newly formed University of Maryland St. Joseph Medical Center has appointed Dr. Mohan Suntha as its president and chief executive officer.
The news was announced Nov. 15 and is pending the anticipated transfer of the current St. Joseph Medical Center to the University of Maryland Medical System Dec. 1. The Catholic Review reported in August that this sale must be approved by the Archdiocese of Baltimore.
Former Maryland State senator Francis X. Kelly, who has been appointed chairman of the board of the University of Maryland St. Joseph Medical Center Board of Directors, said he has worked closely with Dr. Suntha over the past five years.
“In addition to being an outstanding radiation oncologist, as a graduate of the Wharton School of Business, Dr. Suntha is ideally qualified to be CEO of St. Joseph,” Kelly said. “He is a strong, personable and decisive leader.”
Dr. Suntha is vice chairman of the Department of Radiation Oncology at the University of Maryland School of Medicine and is the Marlene and Stewart Greenebaum Professor of Radiation Oncology and associate director of clinical affairs at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. He has been part of the UMMS transition team working on the acquisition of St. Joseph Medical Center from Catholic Health Initiatives.
UMMS and Catholic Health Initiatives of Denver and St. Joseph Medical Center in Towson announced Nov. 14 that they are moving forward with a variety of activities needed to transfer the assets of SJMC to UMMS Dec. 1. As part of the transaction, UMMS has formed the University of Maryland St. Joseph Medical Center, LLC, which will take over all hospital operations once the assets have been transferred and the transaction is closed.
Dr. Suntha graduated from Jefferson Medical College in 1990 and received his MBA from the Wharton School of Business at the University of Pennsylvania in 2009. He has distinguished himself with his research, which focuses on the design and implementation of novel combined modality trials aimed at improving the therapeutic outcome for patients diagnosed with thoracic and head and neck malignancies.
Copyright © Nov. 15, 2012 CatholicReview.org